Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review
Open Access
- 23 January 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 96 (2), 226-230
- https://doi.org/10.1038/sj.bjc.6603562
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic reviewHealth Technology Assessment, 2007
- Caring for survivors of childhood cancers: The size of the problemEuropean Journal of Cancer, 2006
- Cardioprotective interventions for cancer patients receiving anthracyclinesPublished by Wiley ,2005
- The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemiaThe New England Journal of Medicine, 2004
- Does anthracycline administration by infusion in children affect late cardiotoxicity?British Journal of Haematology, 2004
- Late anthracycline cardiotoxicity after childhood cancerCancer, 2003
- Early identification of anthracycline cardiomyopathy: possibilities and implications.Archives of Disease in Childhood, 1996
- Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive careSupportive Care in Cancer, 1996
- Protective effect of Coenzyme Q10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphomaMolecular Aspects of Medicine, 1994
- CARDIAC TOXICITY OF DAUNORUBICINThe Lancet, 1969